Central Immunology Lab for AIDS Vaccine Clinical Trials

Bolognesi, Dani P.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research and Development Contracts (N01)
• Project #: N01AI065305-000
• Application #: 2296629
• Project Start: 1996-04-17
• Project End: 2003-04-16
• Budget Start: 1996-04-17
• Budget End: 1997-04-16
• Fiscal Year: 1996

Institution

• Name: Duke University
• Department: Surgery
• Type: Schools of Medicine
• DUNS #: 071723621
• City: Durham
• State: NC
• Country: United States
• Zip Code: 27705

Publications

Evans, T G; McElrath, M J; Matthews, T et al. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19:2080-91

Ferrari, G; Neal, W; Jones, A et al. (2001) CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol Lett 79:37-45

Ferrari, G; Kostyu, D D; Cox, J et al. (2000) Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 16:1433-43

Belshe, R B; Gorse, G J; Mulligan, M J et al. (1998) Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12:2407-15

Ferrari, G; Humphrey, W; McElrath, M J et al. (1997) Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94:1396-401